M&A

News

Alzheimer's biotech Korsana to go public via reverse merger

By merging with Cyclerion, Korsana will get a Nasdaq listing and additional cash to develop its new-generation amyloid-targeting drug for Alzheimer's.

News

Biogen swoops on Apellis with $5.6bn offer

In today's second sizeable M&A deal, Biogen has agreed to buy Apellis for around $5.6 billion, building on its aspirations in nephrology.

News

Eli Lilly makes $7.8bn takeover play for Centessa

Sleep disorder specialist Centessa is heading for an acquisition by Eli Lilly, which has offered $6.3bn for the US and UK-based biotech.

News

Otsuka grows in neuroplastogens with $1.225bn Transcend buy

Otsuka has agreed to acquire Transcend Therapeutics and its MDMA-based neuroplastogen drug candidate for PTSD, heading for phase 3 trials.

News

Recordati gets €10.9bn takeover bid from private equity firm

Recordati has received a takeover offer from private equity group CVC that, if completed, would delist it from the Italian stock exchange.

News

Novartis snaps up food allergy firm Excellergy for $2bn

Novartis has signed its second M&A deal in the space of a week, pledging to pay up to $2 billion to acquire US food allergy drug developer Excellergy.

Alzheimer's biotech Korsana to go public via reverse merger

Biogen swoops on Apellis with $5.6bn offer

Eli Lilly makes $7.8bn takeover play for Centessa

Otsuka grows in neuroplastogens with $1.225bn Transcend buy

Recordati gets €10.9bn takeover bid from private equity firm

Novartis snaps up food allergy firm Excellergy for $2bn

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

M&A

Editor's Picks